Daily Endocrinology Research Analysis
Analyzed 38 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic, epidemiologic, and interventional endocrinology. A single-cell multi-omic study reveals an NKX2.2–CLEC16A/endosomal axis essential for human pancreatic endocrine differentiation and models autoimmune-like features of type 1 diabetes with pharmacologic rescue. Population data show dual liver–pancreas fat deposition elevates cardiometabolic multimorbidity and cardiac remodeling risk, while an RCT demonstrates tighter glycemic targets in gestational diabetes reduce large-for-gestational-age births and cesarean deliveries at the expense of more insulin use.
Research Themes
- Pancreatic endocrine development and autoimmune mechanisms in T1D
- Ectopic organ fat (liver–pancreas) and cardiometabolic multimorbidity
- Perinatal glycemic targets and obstetric-neonatal outcomes
Selected Articles
1. Single-cell multi-omic analyses highlight the essential role of NKX2.2-CLEC16A/endosomal pathway for human pancreatic differentiation and function.
Using an expandable pancreatic progenitor-to-islet platform, the authors map transcriptomic and chromatin dynamics and infer regulatory networks that govern endocrine lineage decisions. They identify an essential NKX2.2–CLEC16A/endosomal axis and create a human stem cell model with autoimmune-like T1D features via CLEC16A knockout, discovering pharmacologic rescuers of CLEC16A deficiency.
Impact: This study provides a mechanistic blueprint for human pancreatic endocrine differentiation and a tractable T1D-like human model with actionable rescue strategies, advancing therapeutic target discovery.
Clinical Implications: While preclinical, the identification of the NKX2.2–CLEC16A axis and pharmacologic rescuers suggests targets for preserving beta-cell function and modulating endosomal pathways in autoimmune diabetes.
Key Findings
- Systems-level single-cell multi-omics defined regulatory networks controlling ePP self-renewal, endocrine bifurcation, and islet function.
- An essential NKX2.2–CLEC16A/endosomal pathway axis was identified as critical for human pancreatic differentiation.
- CLEC16A knockout produced an autoimmune-like human T1D model and enabled discovery of pharmacologic rescuers for CLEC16A deficiency.
Methodological Strengths
- Integrated single-cell transcriptomic and chromatin profiling across differentiation stages
- Functional perturbation (CLEC16A knockout) with pharmacologic rescue screening in a human stem cell platform
Limitations
- Findings are based on in vitro human stem cell models and may not fully recapitulate in vivo immune and metabolic contexts
- Translational efficacy and safety of identified rescuers require in vivo validation
Future Directions: Validate the NKX2.2–CLEC16A axis and pharmacologic rescuers in in vivo models; integrate patient-derived immune components to model autoimmune interactions; assess translational potential in early-phase trials.
Investigating the gene regulatory programs directing stem cell differentiation can provide new insights into cell fate decision. Recently, we have developed an expandable pancreatic progenitor (ePP) platform, but the detailed characterization is lacking. Here, we perform systems-level characterization of the ePP-islet system. We not only define the dynamic and coordinated transcriptomic and chromatin landscapes of pancreatic differentiation but also infer the sophisticated gene regulatory networks that govern ePP self-renewal, control endocrine cell fate bifurcation, and regulate islet function. In addition, we identify the essential roles of the NKX2.2-CLEC16A/endosomal pathway axis. Unexpectedly, we have developed an authentic human stem cell-based model with autoimmune-like characteristics for type 1 diabetes by CLEC16A knockout and further identified effective pharmacological rescuers for CLEC16A deficiency. Notably, this study provides rich information and highlights the ePP-islet system as a powerful platform for uncovering the molecular mechanisms of cell fate decision, paving the way for therapeutic applications.
2. Liver-Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction.
Across a biopsy-proven MASLD cohort and the UK Biobank, pancreatic steatosis correlated with more severe liver histology and, when combined with MASLD, additively increased the risk of incident cardiometabolic multimorbidity and adverse cardiac remodeling. Proteomics implicated lysosomal and glycosaminoglycan-degrading pathways, highlighting dual-organ steatosis as a high-risk metabolic phenotype.
Impact: Defines a dual-organ ectopic fat phenotype with prognostic significance for multimorbidity and cardiac structure/function, integrating histology, imaging, and proteomics.
Clinical Implications: Assessment of both hepatic and pancreatic fat may refine cardiometabolic and cardiac risk stratification; dual-organ steatosis could guide intensified prevention (e.g., weight loss, metabolic therapies) and cardiac surveillance.
Key Findings
- Pancreatic steatosis associated with more severe MASLD histology (steatosis, lobular inflammation, fibrosis) in a biopsy-proven cohort.
- In UK Biobank, dual-organ steatosis (MASLD + PS) increased incident cardiometabolic multimorbidity risk (HR 2.013; 95% CI 1.219–3.322) and was linked to higher LV mass and impaired ventricular function.
- Proteomics highlighted lysosomal catabolic and glycosaminoglycan-degrading pathways, with heparan sulfate proteoglycan catabolism as a hallmark of dual-organ involvement.
Methodological Strengths
- Biopsy-proven MASLD cohort to anchor histological severity associations
- Large population-based cohort (UK Biobank) with prospective follow-up, CMR phenotyping, and integrative proteomics
Limitations
- Observational design with potential residual confounding and selection biases
- Pancreatic fat assessment modalities and median 5.6-year follow-up may limit causal inference and long-term extrapolation
Future Directions: Prospective interventional trials targeting dual-organ steatosis; mechanistic studies to validate lysosomal and proteoglycan pathways; development of combined hepatic–pancreatic imaging risk scores.
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic steatosis (PS) are interconnected ectopic fat conditions linked to cardiometabolic dysregulation. Their combined effect on the long-term risk of cardiometabolic multimorbidity (CMM; ≥ 2 of diabetes, hypertension, coronary heart disease, and stroke) and cardiac remodelling remains unclear. METHODS: We examined cross-sectional associations between PS and the severity of MASLD histology in a biopsy-proven MASLD cohort from China. Subsequently, using the UK Biobank, we assessed the long-term risk of developing both incident CMM and cardiac structural/functional alterations (via cardiac magnetic resonance [CMR]) associated with single-organ versus dual-organ steatosis. Exploratory proteomic profiling was performed to identify potential molecular pathways. RESULTS: In the biopsy-proven cohort (n = 482), both continuous pancreatic proton density fat fraction and PS status were associated with severe hepatic steatosis, lobular inflammation, and fibrosis (all p < 0.05). In the UK Biobank cohort (n = 16 408; median follow-up of 5.6 years), the coexistence of MASLD and PS additively increased the risk of new-onset CMM (HR = 2.013, 95% CI: 1.219-3.322, p = 0.006). Dual-organ steatosis was also associated with marked cardiac alterations, specifically increased left ventricular mass and impaired ventricular function. Proteomics revealed upregulation of lysosomal catabolic and glycosaminoglycan-degrading pathways in dual-organ steatosis compared to single-organ steatosis. Gene Ontology highlighted heparan sulphate proteoglycan catabolism as a hallmark of dual-organ involvement. CONCLUSION: PS is associated with greater severity of MASLD histology, and the concomitant involvement of both the liver and pancreas drives a higher risk of CMM and cardiac remodelling.
3. Tight versus less tight glycaemic targets for women with gestational diabetes mellitus: a randomised controlled trial.
In a single-center RCT of 650 women with GDM, tighter glycemic targets reduced large-for-gestational-age births, cesarean delivery, and gestational weight gain compared with less tight targets, but required more insulin. Serious adverse events and maternal hypoglycemia were rare and similar between groups.
Impact: Provides randomized evidence to refine glycemic targets in GDM with clear maternal-fetal benefits and manageable trade-offs in pharmacotherapy.
Clinical Implications: Clinicians may consider adopting tighter glycemic thresholds in GDM to reduce LGA and cesarean delivery, with anticipation of increased insulin initiation and monitoring.
Key Findings
- Tight targets reduced LGA incidence (19.2% vs 26.5%; aRR 0.61, 95% CI 0.42–0.89).
- Cesarean delivery rates and gestational weight gain were lower with tight targets.
- Insulin use increased with tight targets (32.6% vs 21.6%; aRR 1.67), without increases in serious complications or maternal hypoglycemia.
Methodological Strengths
- Randomized controlled design with intention-to-treat analysis and high completion (96.3%)
- Prespecified, clinically meaningful primary endpoint (LGA) with standardized glycemic targets
Limitations
- Single-center, open-label design may limit generalizability and introduce performance bias
- Long-term maternal and offspring metabolic outcomes were not assessed
Future Directions: Multicenter, blinded or pragmatic trials to confirm generalizability; evaluate long-term maternal and offspring metabolic outcomes and cost-effectiveness of tighter targets.
AIMS: To determine if tight glycemic control in gestational diabetes mellitus (GDM) reduces adverse outcomes compared to less tight targets. METHODS: In a single-center, open-label randomized controlled trial, 650 women with GDM (singleton pregnancies, 12-31 weeks' gestation) were randomized to tight (fasting < 5.1 mmol/L, 1-h postprandial < 7.0 mmol/L) or less tight (fasting < 5.3 mmol/L, postprandial < 7.8 mmol/L) targets. The primary outcome was the incidence of large-for-gestational-age (LGA) infants. Secondary outcomes included measures of maternal and neonatal health, analyzed by intention-to-treat. RESULTS: Of 650 enrolled women, 626 (96.3%) completed the trial with primary outcome data. The tight-target group had a lower incidence of LGA (19.2% vs. 26.5%; adjusted relative risk (aRR) 0.61, 95%CI 0.42-0.89; p = 0.010), lower cesarean rates (23% vs. 29.9%; aRR 0.63; p = 0.012), and reduced gestational weight gain (10.1 vs. 10.7 kg; p = 0.006). Insulin use was higher with tight targets (32.6% vs. 21.6%; aRR 1.67; p = 0.005). Serious complications and maternal hypoglycemia rates were low and comparable. CONCLUSION: Tight glycemic targets in GDM lower the risk of LGA births, cesarean delivery, and excess maternal weight gain without increasing severe adverse events, though they necessitate more frequent insulin therapy.